Premium
Campthotecin Design and Delivery Approaches for Elevating Anti‐Topoisomerase I Activities in Vivo
Author(s) -
BURKE THOMAS G.,
BOM DAVID
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb07023.x
Subject(s) - camptothecin , in vivo , drug delivery , topoisomerase , pharmacology , drug , chemistry , targeted drug delivery , pharmaceutical sciences , liposome , medicine , in vitro , biochemistry , biology , microbiology and biotechnology , organic chemistry
A bstract : The camptothecins as a class have exhibited unique dynamics and reactivity in vivo , with respect to both drug hydrolysis and blood protein interactions. These factors have confounded their pharmaceutical development and clinical implementation. Recent bench and clinical research alike indicates that the combination of medicinal chemical and drug delivery approaches has been and will continue to be highly valuable in improving the overall therapeutic indices of camptothecin‐based anti‐topoisomerase I therapies. In the future the development of camptothecin analogues that exhibit highly specific human albumin interactions will likely be avoided, and agents such as the highly lipophilic DB‐67 analogue with improved tissue stability will be evaluated. Drug delivery scientists will also devise better ways of targeting camptothecin therapies to solid tumors by using carriers such as tumor‐targeted long‐circulating liposomes.